Proof of stability of an RSV Controlled Human Infection Model challenge agent.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-422X (Electronic) Linking ISSN: 1743422X NLM ISO Abbreviation: Virol J Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, 2004-
    • Subject Terms:
      Respiratory Syncytial Virus, Human*/physiology ; Respiratory Syncytial Virus, Human*/genetics ; Respiratory Syncytial Virus Infections*/virology ; Epithelial Cells*/virology ; Viral Load*; Humans ; Virus Replication ; Cryopreservation/methods ; Cells, Cultured
    • Abstract:
      In 2018, SGS Belgium NV developed RSV-NICA (Respiratory Syncytial Virus-Nasobronchial Infective Challenge Agent), an RSV type A challenge agent for use in RSV Controlled Human Infection Model (CHIM) studies.It is widely recognized that the stability of RSV can be influenced by a variety of environmental parameters, such as temperature and pH. Consequently, our objective was to evaluate the stability of the viral titer of RSV-NICA following five years of controlled storage and to determine the uniformity of the viral titers across different vials of a GMP-qualified batch of RSV-NICA. In addition, we examined the capacity of RSV-NICA to infect human primary airway epithelial cells (MucilAir™), the principal target cells of RSV, and evaluated the influence of single and recurrent freeze-thaw cycles on the infectious viral titer of the challenge agent.The aliquoted RSV-NICA virus stock was subjected to standard virological and molecular methods to gather data on the titer and consistency of the viral titer contained within 24 representative vials of the stock. Our findings illustrate that over a span of five years of cryo-storage, the infectious viral titer in 75% of the tested vials exhibited a comparable average infectious viral titer (4.75 ± 0.06 vs 4.99 ± 0.11; p-value = 0.14). A considerable reduction down to an undetectable level of infectious virus was observed in the remaining vials. RSV-NICA demonstrated its capacity to effectively infect differentiated human airway epithelial cells, with active virus replication detected in these cells through increasing RSV genome copy number over time. Virus tropism for ciliated cells was suggested by the inhibition of cilia beating coupled with an increase in viral RNA titers. No discernable impact on membrane barrier function of the epithelial lung tissues nor cytotoxicity was detected. Pooling of vials with infectious titers > 4.0 log 10 TCID 50 /ml and freeze-thawing of these combined vials showed no deterioration of the infectious titer. Furthermore, pooling and re-aliquoting of vials spanning the entire range of viral titers (including vials with undetectable infectious virus) along with subjecting the vials to three repeated freeze-thaw cycles did not result in a decrease of the infectious titers in the tested vials.Taken together, our findings indicate that long-term cryo-storage of vials containing RSV-NICA challenge agent may influence the infectious viral titer of the virus, leading to a decrease in the homogeneity of this titer throughout the challenge stock. However, our study also demonstrates that when heterogeneity of the infectious titer of an RSV stock is observed, rounds of pooling, re-aliquoting and subsequent re-titration serve as an effective method not only to restore the homogeneity of the infectious titer of an RSV-A stock, but also to optimize patient-safety, scientific and operational aspects of viral inoculation of study participants during at least the period of one RSV CHIM trial. RSV-NICA is a stable, suitable CHIM challenge agent that can be utilized in efficacy trials for RSV vaccines and antiviral entities.
      (© 2024. The Author(s).)
    • References:
      J Gen Virol. 2019 Jul;100(7):1112-1122. (PMID: 31184573)
      J Virol. 2002 Jun;76(11):5654-66. (PMID: 11991994)
      Viruses. 2022 Mar 25;14(4):. (PMID: 35458409)
      Eur Respir J. 2021 Apr 1;57(4):. (PMID: 33060153)
      Eur Respir Rev. 2022 Nov 15;31(166):. (PMID: 36384703)
      Viruses. 2018 Jan 02;10(1):. (PMID: 29301313)
      Bio Protoc. 2016 May 20;6(10):. (PMID: 30079370)
      J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583. (PMID: 30880339)
      PLoS One. 2014 Nov 21;9(11):e113100. (PMID: 25415360)
      Front Immunol. 2019 Sep 12;10:2152. (PMID: 31572372)
      N Engl J Med. 2022 Feb 17;386(7):655-666. (PMID: 35172056)
      Lancet. 2022 May 28;399(10340):2047-2064. (PMID: 35598608)
      Front Cell Infect Microbiol. 2021 Sep 10;11:690621. (PMID: 34568087)
      Infect Dis Ther. 2021 Mar;10(Suppl 1):5-16. (PMID: 33660239)
      Lancet Infect Dis. 2023 Jan;23(1):e2-e21. (PMID: 35952703)
      Bull Math Biol. 2021 Nov 30;84(1):11. (PMID: 34850293)
      Methods Mol Biol. 2013;1030:365-72. (PMID: 23821282)
      Virol Sin. 2021 Feb;36(1):141-144. (PMID: 32458296)
      Mol Pharm. 2005 Nov-Dec;2(6):491-9. (PMID: 16323956)
      N Engl J Med. 2022 Jun 23;386(25):2377-2386. (PMID: 35731653)
      Vaccine. 1996 Oct;14(15):1417-20. (PMID: 8994316)
    • Contributed Indexing:
      Keywords: CHIM; Infectivity/attack rate; MucilAir™; Plaque; RSV-NICA; TCID50; Titration
    • Publication Date:
      Date Created: 20240515 Date Completed: 20240516 Latest Revision: 20240518
    • Publication Date:
      20240518
    • Accession Number:
      PMC11097566
    • Accession Number:
      10.1186/s12985-024-02386-y
    • Accession Number:
      38750558